Trending...
- Sairahaz Highlights Moissanite Wedding Rings as Couples Seek Value and Individuality in 2026
- The Prolific Writer, Producer "Hunter" Is Bringing New Music For Summer Release
- Wright Enterprises Salutes DIFF's 2026 Feature Lineup as Juneteenth and Obama Presidential Center Opening Create a Historic Cultural Moment
REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the Jeffries Virtual Healthcare Conference to be held June 2 at 1:30 p.m. ET (10:30 a.m. PT). A live webcast link of the event can be found on the Company's website at http://ir.acelrx.com/upcoming-events. Management will also be hosting one-on-one investor meetings throughout the day.
For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
More on The Californer
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.
SOURCE AcelRx Pharmaceuticals, Inc.
Related Links
www.acelrx.com
For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
More on The Californer
- Boston Industrial Solutions Introduces High-Performance Primer for Bonding Liquid Silicone to Epoxy
- Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
- Governor Newsom announces $227 million to combat illicit cannabis activity and protect California communities
- Verbica Challenges Panetta to a Televised Debate on the Issues
- Salt Lake City Families Turn to Private Autopsy Services for Faster Answers After Unexpected Loss
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.
SOURCE AcelRx Pharmaceuticals, Inc.
Related Links
www.acelrx.com
Filed Under: Business
0 Comments
Latest on The Californer
- RadioMobile Announces Sponsorship of the Burn Institute's Firefighter Demolition Derby & Fire & Safety Expo
- What If Creativity Is Your Natural State? "The Spark Sessions" Reclaims It as a Birthright
- HomeCentris Home Health Achieves 5-Star CMS Rating
- gptmelo Helps Brands Become More Visible in AI Search Results
- Shabnam Vafaee & Peter Sharokhi's Dream of helping people
- California: What they're saying: Leaders thankful for continued resources to help Los Angeles fire survivors
- Senior Technology Launches on iOS and Android
- Patchdesign.ai Launches First AI-Powered Platform to Deliver Custom Patches Worldwide in 10 Days
- California's earthquake warning system notified over one million people ahead of Northern California quake
- Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
- California: Governor Newsom welcomes FEMA extension to help Los Angeles fire survivors continue recovery
- KooLooAI Selected Among Top 100 Companies in Pepperdine University's 2026 Most Fundable Companies®
- Governor Newsom convenes the first meeting of California's Tech Fraud Task Force to help strengthen consumer protections
- Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
- Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
- Governor Newsom welcomes first public preview of California Science Center's new Air and Space Center ahead of November opening
- California: Governor Newsom awards $38.2 million to help tribes expand housing and homelessness solutions
- GreenSight and IQ Reseller Partner to Bring AI Pricing to the Secondary Electronics Market
- In the years since Dobbs, California continues to stand firm as a strong reproductive freedom state
- The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth